Peter Špalek
Intravenous immunoglobulins (IVIg) have been used for treating various neuroimmunological diseases. Over the past
years their efficacy could be demonstrated in placebo-controlled, double-blinded clinical trials. Therefore, IVIg should
be principally used according to available data from controlled clinical trials. The use of IVIg has become the first-line
treatment for Guillain-Barré syndrome, rapidly worsening myasthenia gravis, myasthenic crisis, multifocal motor neuropathy
and chronic inflammatory demyelinating polyneuropathy. Furthermore, IVIg plays an important role in patients
with severe stiff person syndrome, and as a second-line treatment in selected chronic treatment-refractory cases
of polymyositis, dermatomyositis, myasthenia gravis and Lambert-Eaton myasthenic syndrome. IVIg is well tolerated,
easily administered, and is often efficacious with a relatively rapid action. Here we review the indications and recommendations
for the use of IVIg in autoimmune neurologic diseases.